Personalized Medicine

Less Is More: Low-Risk Stage III Colon Cancer Safely Treated with Only 3 Months of Adjuvant Chemotherapy

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Colon Cancer

Chicago, IL—The global International Duration Evaluation of Adjuvant Chemotherapy (IDEA) study suggests that some patients with surgically resected stage III colon cancer can safely and effectively receive only 3 months of chemotherapy instead of the standard 6 months. The data were particularly convincing for patients with low-risk, surgically resected stage III colon cancer. These data set a new standard for the treatment of patients with stage III colon cancer, according to expert opinion presented at the 2017 ASCO annual meeting. [ Read More ]

Abemaciclib, a New CDK4/CDK6 Inhibitor, Added to Fulvestrant Extends PFS in Advanced HR-Positive, HER2-Negative Breast Cancer

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Breast Cancer

Chicago, IL—The addition of the investigational CDK4/CDK6 inhibitor abemaciclib to fulvestrant (Faslodex) extended progression-free survival (PFS) by 7 months in women with hormone receptor (HR)-positive, HER2-negative advanced breast cancer, reported George W. Sledge, Jr, MD, Professor, Medical Oncology, Stanford University Medical Center, Palo Alto, CA, who presented the results of a large study at the 2017 ASCO annual meeting. [ Read More ]

Osimertinib Extends Progression-Free Survival in EGFR T790M–Positive Lung Cancer with CNS Metastases

Wayne Kuznar

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Lung Cancer

Chicago, IL—Osimertinib (Tagrisso) extends progression-free survival (PFS) compared with standard chemotherapy in patients with EGFR T790M mutation–positive non–small-cell lung cancer (NSCLC) who have central nervous system (CNS) metastases, reported Marina C. Garassino, MD, Thoracic Oncology Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, at the 2017 ASCO annual meeting. [ Read More ]

Olaparib First PARP Inhibitor to Show Advantage in BRCA-Positive Breast Cancer

Wayne Kuznar

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Breast Cancer

Chicago, IL—The PARP inhibitor olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with standard chemotherapy in women with HER2-negative metastatic breast cancer with a germline BRCA mutation. Disease progression was delayed by approximately 3 months with olaparib in the multinational, randomized, open-label, phase 3 OlympiAD clinical trial, reported Mark E. Robson, MD, Clinic Director, Clinical Genetics Service, Memorial Sloan Kettering Cancer Center, New York City, at the 2017 ASCO annual meeting. [ Read More ]

Alectinib New Standard of Care for ALK-Positive Non–Small-Cell Lung Cancer

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Lung Cancer

Chicago, IL—Alectinib (Alecensa), a next-generation anaplastic lymphoma kinase (ALK) inhibitor, was called a new standard of care for patients with ALK mutation–positive non–small-cell lung cancer (NSCLC), based on results of the phase 3 ALEX clinical trial, which were presented at the 2017 ASCO annual meeting. [ Read More ]

Daratumumab Added to Carfilzomib, Lenalidomide, and Dexamethasone: Safe and Tolerable in Patients with Newly Diagnosed Multiple Myeloma

Chase Doyle

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Multiple Myeloma

Chicago, IL—In patients with newly diagnosed multiple myeloma, the addition of daratumumab to carfilzomib (Kyprolis), lenalidomide (Revlimid), and dexamethasone (ie, the KRd regimen) is showing promise as a frontline treatment regimen. According to the results of an open-label, phase 1b study presented at ASCO 2017, induction therapy with the KRd regimen was well-tolerated, and the overall safety profile was consistent with previous reports for KRd, with no additional toxicity observed with the addition of daratumumab. Moreover, the study investigators reported that the regimen was very effective, with 100% overall response rate observed. [ Read More ]

Checkpoint Inhibitors Show Promise in Patients with Mesothelioma

Phoebe Starr

August 2017, Vol 8, No 4 | Payers’ Perspectives In Oncology: ASCO 2017 Highlights - Immunotherapy

Chicago, IL—Immunotherapy holds promise as second-line or third-line treatment of patients with malignant pleural mesothelioma, a rare cancer with increasing incidence. Early findings from the ongoing, phase 2 MAPS-2 clinical trial showed that immunotherapy slowed the growth of malignant pleural mesothelioma after relapse, reported lead investigator Arnaud Scherpereel, MD, PhD, Head, Pulmonary and Thoracic Oncology Department, University Hospital of Lille, France, at the 2017 ASCO annual meeting. MAPS-2 is the largest clinical trial to date of immune checkpoint inhibitor therapy in patients with malignant pleural mesothelioma. [ Read More ]